Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2013

Li Yuan-Yuan, Lam Sze-Kwan, Mak Judith Choi-Wo, Zheng Chun-Yan, Ho James Chung-Man

Abstract excerpt

PURPOSE: Erlotinib is a commonly used tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). Autophagy is a catabolic process in response to stress and deprivation of nutrients. This study aims to investigate whether autophagy confers acquired resistance to erlotinib treatment in NSCLC. METHODS: Four NSCLC cell lines (HCC827, HCC4006, H358 and H1975) with different epidermal growth factor receptor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis Regulatory Proteins
Share to Autophagy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Autophagy-Related Protein 5

Share to Beclin-1

Share to Erlotinib Hydrochloride

Share to Gene Knockdown Techniques

Share to Microtubule-Associated Proteins

Share to Quinazolines

Source

Identifiers

PMID: 23769318
DOI: 10.1016/j.lungcan.2013.05.012

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.PMID 23769318Read ↗

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancerSemantic proximity Read ↗

EGFR signaling and autophagy dependence for growth, survival, and therapy resistanceSemantic proximity Read ↗

EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.Semantic proximity Read ↗

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to ErlotinibSemantic proximity Read ↗

Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.Semantic proximity Read ↗

Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model.Semantic proximity Read ↗

An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.Semantic proximity Read ↗

Targeting EGFR degradation by autophagosome degraders.Semantic proximity Read ↗

Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.Semantic proximity Read ↗

Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivoSemantic proximity Read ↗

Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.